Celadon Pharmaceuticals Plc

Celadon's goal is to become the provider and partner of choice for pharmaceutical cannabinoid-based medicines in the highly regulated UK market and is initially focusing on the chronic pain market.

Celadon is believed to be one of the first pharmaceutical companies in the UK to receive a Home Office licence, following approval from the Medicines and Healthcare products Regulatory Agency ("MHRA") to apply for the licence, allowing it to grow high tetrahydrocannabinol ("THC") medicinal cannabis.